Study summary

A PARP inhibitor delayed progression in men with DNA-repair gene changes

AMPLITUDE trial (niraparib) · 696 men, phase 3 · Published October 2025, Nature Medicine

What was tested

Niraparib, a PARP inhibitor pill, or placebo added to abiraterone and prednisone for metastatic castration-sensitive prostate cancer with BRCA or other DNA-repair (HRR) gene alterations.

What they found

What it means

Makes genetic testing at diagnosis more important for men with metastatic disease.

Nat Med, via PubMed ↗ Trial record NCT04497844 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.